Xilio Therapeutics Inc (XLO) Actualités

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

WALTHAM, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

Initiated enrollment in Phase 2 clinical trial of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report